On June 12, 2019 Debiopharm (Debiopharm – www.debiopharm.com) and Ipsen (www.ipsen.com) reported renewal of their Decapeptyl agreement, which extends and strengthens their strategic partnership through 2034 for the development, manufacturing and distribution of Decapeptyl across Europe and certain Asian and African markets (Press release, Ipsen, JUN 12, 2019, View Source [SID1234537019]). Having established their collaboration in the 1980s, this extension represents a long-term commitment to patients, offering the benefits of Decapeptyl in the treatment of metastatic and non-metastatic patients with locally advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty and endocrine-responsive early-stage breast cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the renewed agreement, both parties will co-develop novel formulations and explore additional indications for other patient populations with high unmet needs.
"Our continued partnership remains critical to ensure that patients maintain access to Decapeptyl therapy for their various conditions. Furthermore, this renewed agreement represents an opportunity to refine and refocus our collaboration by further exploring our co-development capacity to potentially identify how Decapeptyl can respond to more unmet patient needs."
Thierry Mauvernay, President & Delegate of the Board Group, Debiopharm
"We are delighted to renew and extend this partnership with Debiopharm. This collaboration has been – and continues to be – a testament to our commitment to patients and our shared passion with strategic partners."
Ivana Magovčević-Liebisch, Executive Vice-President, Chief Business Officer
About Decapeptyl
Decapeptyl (triptorelin pamoate) is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH), currently available in three sustained-release formulations (1, 3 and 6 months). First registered in France in 1986, triptorelin is currently marketed in more than 80 countries, being the market leader in many territories worldwide. The alliance between Debiopharm and Ipsen for Decapeptyl has successfully delivered sustained market growth with €372.6 million total sales in 2018, representing 8.1% annual growth.